University of Connecticut Health Center - Know Better Care

Profiles Research Networking Software

Bruce E Strober MD, PhD
Title Assistant Professor
Institution UConn Health Center
Department Dermatology
Address UConn Dermatology Associates, MC 6231
21 South Road
Farmington, CT 06032
Telephone 860-679-7692
Fax
Email
Other Positions
Title Director of Clinical Trials
Institution UConn Health Center
Department Dermatology
Publications
1. Strober B. Biologic therapy for psoriasis: early response implies future success. Br J Dermatol. 2013 Dec; 169(6):1178-9.
  View in: PubMed
 
2. Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013 Nov; 169(5):992-9.
  View in: PubMed
 
3. Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, Elewski BE, Turner-Bowker DM, Shields AL, Gwaltney CJ, Lebwohl M. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013 Sep-Oct; 16(6):1014-22.
  View in: PubMed
 
4. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep; 6(9 Suppl):S2-S20.
  View in: PubMed
 
5. Babalola O, Strober BE. Management of psoriasis in pregnancy. Dermatol Ther. 2013 Jul-Aug; 26(4):285-92.
  View in: PubMed
 
6. Babalola O, Strober BE. Treatment of atopic dermatitis in pregnancy. Dermatol Ther. 2013 Jul-Aug; 26(4):293-301.
  View in: PubMed
 
7. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013 Apr; 168(4):844-54.
  View in: PubMed
 
8. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther. 2013 Jul; 13(7):1039-47.
  View in: PubMed
 
9. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan; 149(1):25-32.
  View in: PubMed
 
10. de Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol. 2013 Jan; 168(1):210-2.
  View in: PubMed
 
11. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
  View in: PubMed
 
12. Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol. 2012 Dec; 167(6):1374-81.
  View in: PubMed
 
13. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012 Oct; 11(10):1210-7.
  View in: PubMed
 
14. De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012 Oct; 11(10):1224-6.
  View in: PubMed
 
15. Santoro FA, Rothe MJ, Strober BE. Ethical considerations when prescribing biologics in dermatology. Clin Dermatol. 2012 Sep-Oct; 30(5):492-5.
  View in: PubMed
 
16. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012 Sep; 167(3):668-77.
  View in: PubMed
 
17. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012 Sep; 167(3):649-57.
  View in: PubMed
 
18. Marmon S, De Souza A, Strober BE. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J. 2012 Jun; 18(6):13.
  View in: PubMed
 
19. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec; 2(1):2.
  View in: PubMed
 
20. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2(1):1.
  View in: PubMed
 
21. Strober BE, Armour K, Romiti R, Smith C, Tebbey PW, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012 Feb; 66(2):317-22.
  View in: PubMed
 
22. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan; 148(1):95-102.
  View in: PubMed
 
23. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14.
  View in: PubMed
 
24. Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011 Oct 1; 12(5):321-37.
  View in: PubMed
 
25. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012 May; 66(5):731-41.
  View in: PubMed
 
26. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
  View in: PubMed
 
27. De Souza A, Ali-Shaw T, Strober BE, Franks AG. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011 Aug; 147(8):896-8.
  View in: PubMed
 
28. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep; 165(3):661-8.
  View in: PubMed
 
29. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: consensus conference. J Am Acad Dermatol. 2011 Jun; 64(6):1179.
  View in: PubMed
 
30. Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011 Apr; 64(4):671-81.
  View in: PubMed
 
31. De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011; 69(2):185-7.
  View in: PubMed
 
32. Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, Ferguson A, Ecker RC, Kopp T, Weise-Riccardi S, Guettner A, Stingl G. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology. 2011 Feb; 222(1):36-48.
  View in: PubMed
 
33. Brauer JA, Mandal R, Walters R, Solomon G, Kundu RV, Strober BE. Disseminated superficial porokeratosis. Dermatol Online J. 2010; 16(11):20.
  View in: PubMed
 
34. Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010 Aug; 9(8):928-37.
  View in: PubMed
 
35. Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol. 2010 Jun; 162(6):1349-58.
  View in: PubMed
 
36. Levine D, Strober BE. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Semin Cutan Med Surg. 2010 Mar; 29(1):28-34.
  View in: PubMed
 
37. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14; 362(2):118-28.
  View in: PubMed
 
38. Strober BE, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, Siu K, Lustgarten JL, Ross EK, Shapiro J. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2009 Nov; 145(11):1262-6.
  View in: PubMed
 
39. Menon K, Van Voorhees AS, Bebo BF, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010 Feb; 62(2):291-9.
  View in: PubMed
 
40. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46.
  View in: PubMed
 
41. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009 May; 60(5):824-37.
  View in: PubMed
 
42. Marmon S, Strober BE. Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. J Invest Dermatol. 2008 Nov; 128(11):2567-9.
  View in: PubMed
 
43. Victor F, Menon K, Latkowski JA, Fernandez-Obregon A, Strober BE. Efalizumab-associated Guillain-Barre syndrome. Arch Dermatol. 2008 Oct; 144(10):1396-7.
  View in: PubMed
 
44. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008; 3(7):e2719.
  View in: PubMed
 
45. Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB. Rethinking eligibility creep. J Am Acad Dermatol. 2008 Jul; 59(1):165-7; author reply 167.
  View in: PubMed
 
46. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008 Aug; 159(2):322-30.
  View in: PubMed
 
47. Levy MS, Polsky D, Davidson A, Strober BE. Tinea versicolor associated with etanercept therapy. J Am Acad Dermatol. 2008 May; 58(5 Suppl 1):S99-100.
  View in: PubMed
 
48. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008 May; 24(5):1529-38.
  View in: PubMed
 
49. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008 Jun; 58(6):1031-42.
  View in: PubMed
 
50. Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol. 2007 Dec; 57(6):1090-1.
  View in: PubMed
 
51. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan; 58(1):94-105.
  View in: PubMed
 
52. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
  View in: PubMed
 
53. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007 Oct; 157(4):649-55.
  View in: PubMed
 
54. Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007 Jul-Aug; 20(4):270-6.
  View in: PubMed
 
55. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol. 2007 Jul; 157(1):213.
  View in: PubMed
 
56. Henning JS, Gruson LM, Strober BE. Reconsidering liver biopsies during methotrexate therapy. J Am Acad Dermatol. 2007 May; 56(5):893-4.
  View in: PubMed
 
57. Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, Xia HA, Chiou CF, Stevens SR. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis. 2007 Apr; 79(4):322-6.
  View in: PubMed
 
58. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007 Feb; 143(2):239-42.
  View in: PubMed
 
59. Stein JA, Fangman B, Strober B. Actinic granuloma. Dermatol Online J. 2007; 13(1):19.
  View in: PubMed
 
60. Srivastava M, Solomon G, Strober B. Psoriatic onycho-pachydermo periostitis. Dermatol Online J. 2007; 13(1):20.
  View in: PubMed
 
61. Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007 Jan; 156(1):138-42.
  View in: PubMed
 
62. Flood J, Mihalik C, Fleming RR, Strober BE, Zucker DR, Burgoyne DS. The use of therapeutic interchange for biologic therapies. Manag Care. 2007 Jan; 16(1):51-62.
  View in: PubMed
 
63. Leonardi CL, Strober BE. On multiple courses of alefacept. J Am Acad Dermatol. 2006 Nov; 55(5):916-7.
  View in: PubMed
 
64. Paulino LC, Tseng CH, Strober BE, Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol. 2006 Aug; 44(8):2933-41.
  View in: PubMed
 
65. Belsito D, Wilson DC, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober BE, Willetts J, Rutledge ES. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol. 2006 Jul; 55(1):40-6.
  View in: PubMed
 
66. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol. 2006 Jul; 33(7):1442-6.
  View in: PubMed
 
67. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006 May; 142(5):605-12.
  View in: PubMed
 
68. Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, Frankel E, Xia HA, Stevens SR. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006; 17(6):343-52.
  View in: PubMed
 
69. Strober BE. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept. Arch Dermatol. 2005 Dec; 141(12):1602.
  View in: PubMed
 
70. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005 Dec; 9(6):296-302.
  View in: PubMed
 
71. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005 Oct; 53(4):652-9.
  View in: PubMed
 
72. Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A, Shupack JL. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005 Jun; 52(6):1082-4.
  View in: PubMed
 
73. Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol. 2005 Jun; 52(6):1101-2.
  View in: PubMed
 
74. Rosmarin D, Strober BE. The potential of interleukin 12 inhibition in the treatment of psoriasis. J Drugs Dermatol. 2005 May-Jun; 4(3):318-25.
  View in: PubMed
 
75. Strober BE. The treatment of psoriasis with etanercept. Semin Cutan Med Surg. 2005 Mar; 24(1):28-36.
  View in: PubMed
 
76. Rosenberg BE, Strober BE. Acrodermatitis continua. Dermatol Online J. 2004; 10(3):9.
  View in: PubMed
 
77. Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol. 2004 May-Jun; 3(3):270-2.
  View in: PubMed
 
78. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol. 2004 Mar; 140(3):366.
  View in: PubMed
 
79. Arroyo MP, Sanders S, Yee H, Schwartz D, Kamino H, Strober BE. Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. Br J Dermatol. 2004 Mar; 150(3):581-8.
  View in: PubMed
 
80. Saini R, Tutrone WD, Strober BE. The Köbner phenomenon and psoriatic arthritis. Cutis. 2003 Nov; 72(5):405-6.
  View in: PubMed
 
81. Strober BE. Erythrokeratodermia variabilis. Dermatol Online J. 2003 Oct; 9(4):5.
  View in: PubMed
 
82. Strober BE. Pachyonychia congenita, type II. Dermatol Online J. 2003 Oct; 9(4):12.
  View in: PubMed
 
83. Strober BE. Generalized morphea. Dermatol Online J. 2003 Oct; 9(4):24.
  View in: PubMed
 
84. Strober BE. Lupus panniculitis (lupus profundus). Dermatol Online J. 2001 Dec; 7(2):20.
  View in: PubMed
 
85. Gallagher TC, Strober BE. Cutaneous Bacillus anthracis infection. N Engl J Med. 2001 Nov 29; 345(22):1646-7.
  View in: PubMed
 
86. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis. 2001 Feb; 67(2):109-10.
  View in: PubMed
 
87. Strober BE. Tinea capitis. Dermatol Online J. 2001 Feb; 7(1):12.
  View in: PubMed
 
88. Strober BE, Dunaief JL. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol. 1996 Apr; 16(4):1576-83.
  View in: PubMed
 
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile contact profiles@uchc.edu.
 
Keyword
Last Name
Institution
    
 
 
 
Same Department  
Dadras, Soheil Sam
Schaefer, Jochen
Search for (3) people
 
A-Z Index UConn Health Center Disclaimer, Privacy Notice & Copyright Maps & Directions Contact Us © University of Connecticut Health Center